Bosso J A, Black P G
Department of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City 84112.
Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):551-3. doi: 10.1177/106002808802200705.
Twenty-five courses of oral ciprofloxacin were administered to 16 patients experiencing pulmonary exacerbations of cystic fibrosis in an open, uncontrolled trial of efficacy and tolerance. Patients were treated for 7-35 days and efficacy was evaluated based on changes in clinical score, white blood cell count, quantitative bacteriology of sputum, and pulmonary function tests. Most courses of therapy were associated with a positive response with changes in clinical score and forced expiratory volume in one second being statistically significant (p less than 0.05). No side effects to ciprofloxacin were noted. Emergence of bacterial resistance to ciprofloxacin was rare. Ciprofloxacin appears to be effective in patients with cystic fibrosis who are experiencing pulmonary exacerbations associated with susceptible bacterial pathogens.
在一项关于疗效和耐受性的开放性、非对照试验中，对16名患有囊性纤维化肺部加重期的患者给予了25个疗程的口服环丙沙星。患者接受治疗7至35天，并根据临床评分、白细胞计数、痰液定量细菌学和肺功能测试的变化来评估疗效。大多数疗程的治疗都产生了积极反应，临床评分和一秒用力呼气量的变化具有统计学意义（p小于0.05）。未观察到环丙沙星的副作用。对环丙沙星产生细菌耐药性的情况很少见。环丙沙星似乎对患有囊性纤维化且肺部加重期与易感细菌病原体相关的患者有效。
